SigVie-002 | #ESMO26

Sigvotatug vedotin vs docetaxel in advanced NSCLC:

❌ Primary OS endpoint not met.

📈 Encouraging OS/PFS trends in EGFR/ALK WT and 2L subgroups.

🧬 IB6 expression was not clearly predictive of efficacy.

🔬 Further combination trials warranted.

#NSCLC #LungCancer